The QualityStocks Daily Wednesday, May 23rd, 2018

Today's Top 3 Investment Newsletters

MarketClub Analysis (WMLP) +194.03%

NetworkNewsWire (DNAX) +72.87%

StockMarketWatch (AVGR) +72.87%

The QualityStocks Daily Stock List

Vitality Biopharma, Inc. (VBIO)

Stock Beast, SmallCap Network, and Promotion Stock Secrets reported previously on Vitality Biopharma, Inc. (VBIO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s commitment is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, it has developed a unique capability to produce molecules by way of glycosylation, a form of enzymatic biosynthesis that was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products.  Vitality Biopharma is based in Los Angeles, California.

The Company successfully modified cannabidiol (CBD) late in 2015, which is not psychoactive. In ongoing work it has created a novel class of pharmaceuticals called cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while lessening or avoiding the systemic delivery of THC into the bloodstream.

Vitality Biopharma can biosynthesize cannabinoid glycosides (cannabosides) through enzyme biosynthesis.  The Company is one of only a very few groups globally who know how to produce and work with the enzymes that perform glycosylation. It has been centered on it because the same enzymes are used to modify the taste of stevia (steviol glycosides).

In October of 2017, Vitality Biopharma announced the achievement of a biosynthesis breakthrough. It developed a proprietary biosynthesis technology, which can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds called cannabinoid glycosides, or cannabosides.

Vitality Biopharma has introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. It is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation. The Company’s plan is to complete a first-in-man clinical study in the first half of 2018.

The treatment indications it plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome (a severe form of opiate-induced abdominal pain). Last month, Vitality Biopharma announced the pending establishment of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd. This subsidiary will concentrate on and enable the performance of a broad array of cannabinoid genetics research and development programs.

Vitality Biopharma is now planning limited operations in Canada. This is to benefit from Health Canada regulations concerning medical cannabis and the federal commitment to nationwide approval for adult use of cannabis.

This month, Vitality Biopharma announced the discovery of new antimicrobial activity of cannabinoids and its application for treatment of C. difficile-associated diarrhea and colitis. In experiments executed according to guidance by the Clinical Laboratory and Standards Institute (CLSI), the Company determined that cannabinoids (including THC) are effective antibiotics for C. diff, VRE, and an assortment of additional pathogens.

Vitality Biopharma filed a non-provisional international patent application on May 9, 2018, pursuant to the Patent Cooperation Treaty (Appl. No. PCT/US2018/031727) titled “Antimicrobial Compositions Comprising Cannabinoids and Methods of Using the Same.”

Vitality Biopharma, Inc. (VBIO), closed Wednesday's trading session at $1.305, down 2.61%, on 107,319 volume with 123 trades. The average volume for the last 60 days is 78,320 and the stock's 52-week low/high is $1.28/$2.37.


Barfresh Food Group, Inc. (BRFH)

Greenbackers, OTCJournal,  RedChip, Lions of Wall Street, The Wall Street Transcript,  SmallCap Network,  Wall Street Resources, Barchart,,  and SmallCapVoice reported previously on Barfresh Food Group, Inc. (BRFH), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Barfresh Food Group, Inc. is a manufacturer and distributor of unique,  frozen, ready-to-blend beverages. These include smoothies, shakes, and frappes. These products are primarily for restaurant chains and the foodservice industry. Barfresh Food Group and Barfresh Food Group Pty Ltd. in Australia (Barfresh Australia) are under common control.  Barfresh Food Group has its head office in Beverly Hills, California. 

Barfresh Food Group acquired the exclusive international patent rights to its ready-to-blend beverage packs. This is on top of its currently held patent rights in the United States and Canada.

The Company has acquired the intellectual property (IP) for its creative “ready to blend” ingredient packs for North America. Its proprietary, patented system utilizes portion-controlled pre-packaged beverage ingredients. These deliver freshly made smoothies that are fast, cost efficient, and without waste.  
The innovative system combines all the ingredients of a quality smoothie into an individually pre-portioned pack. The pack contains real fruit pieces, low fat frozen yogurt or sorbet, fruit juice,  and  ice. This is subsequently blended with water to create a smoothie.  
Barfresh Food Group announced this past February that it expanded its education program to 77 schools with the recent addition of 37 new schools throughout four States. The expansion builds upon Barfresh’s initial soft launch with Pasco County School District in Florida to supply Barfresh frozen beverages at 30 of their middle and high school cafeterias, as well as its Canadian placement in 10 schools.

Barfresh Food Group is offering four all-natural, “no sugar added” products specifically formulated for the education channel to meet USDA guidelines under its Child Nutrition Program, which permits schools to seek reimbursement for meals served.

In April, Barfresh Food Group announced that it entered into a supply agreement with Niagara Parks, an agency of the Government of Ontario, to provide the Company’s branded smoothies at 10 of the Park’s prime serving locations starting this month, ahead of the tourism season.  Niagara Parks hosts about 12 million visitors each year at the world renowned landmark.

Mr. Riccardo Delle Coste, Barfresh Food Group’s Chief Executive Officer, stated, "Niagara Parks is truly a world class tourist attraction and a marquee win for our business in Canada.  The Park straddles Canada and the United States and we are proud to serve its patrons with our healthy frozen beverages at 10 of the Park’s most visited foodservice locations.”

Barfresh Food Group’s Q1 2018 US GAAP Revenue rose 100 percent to $623,000. The Company expects to achieve more than $1 Million of Revenue in Q2 2018.  


Barfresh Food Group, Inc. (BRFH), closed Wednesday's trading session at $0.6699, down 1.49%, on 7,300 volume with 5 trades. The average volume for the last 60 days is 52,561 and the stock's 52-week low/high is $0.351/$0.82.


Cocrystal Pharma, Inc. (COCP)

Microcapmillionaires,  Promotion Stock Secrets, Wall Street Resources, and PennyStocks Forever reported on Cocrystal Pharma, Inc. (COCP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cocrystal Pharma, Inc. develops novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company employs innovative technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The design of these technologies, including its nucleoside chemistry expertise and market-centered approach to drug discovery, are to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. Cocrystal Pharma has offices in Tucker, Georgia and Bothell, Washington.  
A biotechnology enterprise, the Company’s proprietary technologies revolve around a structure-based drug discovery strategy teamed up with wide-ranging nucleoside experience.  Using techniques called protein cocrystallization and X-ray crystallography,  Cocrystal Pharma quickly identifies novel binding sites, identifies critical inhibitor-protein interactions, and optimizes the structure of the inhibitor in a highly rapid iterative fashion.

Cocrystal Pharma has identified promising, preclinical stage antiviral compounds for unmet medical needs. These include hepatitis, influenza, and norovirus infections.

The Company is developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme crucial to viral replication and are highly conserved between all hepatitis C genotypes. As a result, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.  
Cocrystal Pharma is also developing compounds that inhibit hepatitis C helicase and NS5A, two enzymes important for viral replication. The Company also has identified a picomolar inhibitor of NS5A; another important viral replication protein. Its compounds that target NS5B hepatitis C polymerase, NS5A,  and NS3 helicase will undergo development as a combination treatment.

Recently, Cocrystal Pharma announced that its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open. Cocrystal Pharma is cleared to start its Phase 2a clinical study evaluating CC-31244 for the treatment of hepatitis C virus (HCV) infected individuals.

The Phase 2a study is an open-label study. The design of it is to evaluate the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV drugs. Endpoints of the Phase 2a study include changes in HCV RNA viral load, adverse events and laboratory abnormalities.  The Company expects to begin its Phase 2a study of CC-31244 in Q2 of 2018 and announce data in Q4 of 2018.

For Q1 2018, Cocrystal Pharma reported a Net Loss of roughly $1,553,000 versus a Net Loss of roughly $2,548,000 for the same period in 2017. As of March 31, 2018, the Company had $1.2 million in cash and cash equivalents. 

Cocrystal Pharma, Inc. (COCP), closed Wednesday's trading session at $2.1899, up 9.49%, on 274,128 volume with 700 trades. The average volume for the last 60 days is 54,035 and the stock's 52-week low/high is $1.61/$9.00.


LiCo Energy Metals, Inc. (WCTXF)

OTC Markets, MarketWatch, Stockhouse, InvestorsHub, Barchart, SmallCapVoice, Streetwise Reports, Metals News, and reported on LiCo Energy Metals, Inc. (WCTXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, LiCo Energy Metals, Inc. conducts exploration for metals used in the production of lithium-ion batteries. The Company has four ongoing projects in mining-friendly jurisdictions within the U.S., Canada, and Chile. It has an increasing portfolio of encouraging projects, all with goals of developing battery-grade lithium or cobalt. LiCo Energy Metals has its corporate headquarters in Vancouver, British Columbia.

The Company’s projects include the Glencore Bucke Property, the Teledyne Cobalt Project, the Purickuta Exploitation Project, the Dixie Valley Lithium Project, and the Black Rock Desert Lithium Project. The Glencore property comprises 16.2 hectares. It sits along the west boundary of LiCo’s Teledyne Cobalt Project.

The Teledyne Cobalt Project comprises 5 mining claims and 6 staked crown claims in the Buck and Lorrain Townships, in the district of Temiskaming, Ontario. The project encompasses 115.5 hectares of mining and surface rights, with an additional 439.1 hectares of staked crown claims.

The Purickuta Project comprises160 hectares. It is one of a few "exploitation concessions" granted within the Salar de Atacama, home to roughly 37 percent of the globe’s Lithium production.

LiCo has entered into an option to acquire 100 percent, net 3 percent smelter royalty to acquire 348 claims in the Dixie Valley Exploration Project in Churchill County, Nevada. Additionally, the Company has entered into an option agreement where it may earn an undivided 70 percent interest subject to a 3 percent Net Smelter Return Royalty in the existing Black Rock Desert Lithium Project. This Project comprises 199 placer claims (3,980 acres/1,610 hectares) in southwest Black Rock Desert, Washoe County, Nevada.

Last week, LiCo Energy Metals reported assay results for drill holes TE17-04 and TE17-05 completed on the Teledyne Cobalt Property, positioned 6 km northeast of Cobalt, Ontario. The design of the present drill program was to confirm and extend the existing known mineralization along strike and up and down dip.

A summary of the most significant results of the recent drill core assays include TE17-05 2.32 percent Co over 4.00 m from 126.5 to 130.50 m, including 21.9 percent Co over 0.36 m from 127.64 to 128.00 m; and TE17-05 1.70 percent Co over 6.00 m from 136.00 to 142.00 m.

The summary also includes TE17-04 1.82 percent Co over 6.00 m from 138.00 to 144.00 m, including 5.06 percent Co over 1.75 m from 141.25 to 143.00 m, and 18.70 percent Co over 0.15 m from 141.64 to 141.79 m. LiCo completed 11 diamond drill holes totaling 2,200 m in the fall of 2017 on the Teledyne Cobalt Property.

In addition, last week, LiCo Energy Metals updated its shareholders on the completion on the Glencore Bucke Property Phase 1 diamond drilling program. During the fall of 2017, the Company completed 21 diamond drill holes totaling 1,900 m. The drill program, along with the Phase 1 diamond drilling program completed on the Teledyne Cobalt Property, satisfied the Company’s flow-through financing obligations.

Furthermore, the exploration program at the Glencore Bucke Property satisfied LiCo’s contractual obligations to Glencore plc. LiCo was to incur $250,000 of exploration expenditures on the Property within six months of the approval date.

Mr. Tim Fernback, President and Chief Executive Officer of LiCo Energy Metals, said, “We are very pleased with the results of the Glencore Bucke Phase 1 drill program. We not only were successful in completing the objective of the drill program but also with the overall grade, width and consistency of the mineralization. We are working on the design and amount of meters to be drilled of the Phase 2 drill program which will then be the basis of completing a 43-101 compliant resource estimation, which will be completed in conjunction with the Teledyne Cobalt Project."

LiCo Energy Metals, Inc. (WCTXF), closed Wednesday's trading session at $0.04326, up 3.00%, on 102,996 volume with 23 trades. The average volume for the last 60 days is 557,235 and the stock's 52-week low/high is $0.0327/$0.895.


Rocky Mountain High Brands, Inc. (RMHB)

SmallCapVoice,  Promotion Stock Secrets, PennyPickAlerts, Damn Good Penny Picks, SizzlingStockPicks, WallstreetSurfers, Penny Picks,  ProTrader, Winston Small Cap, and Fortune Stock Alerts reported earlier on Rocky Mountain High Brands, Inc. (RMHB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Rocky Mountain High Brands, Inc. is a consumer goods business headquartered in Dallas, Texas. The Company’s specialty is brand development of health conscious, hemp-infused, food and beverage products and  naturally high alkaline water. Rocky Mountain High Brands has now launched its naturally high alkaline spring water, Eagle Spirit Spring Water. Rocky Mountain High Brands lists on the OTC Markets’ OTCQB.

Rocky Mountain High Brands employs  a hybrid distribution model. This model takes advantage of distribution contacts and brokers, and direct relationships with wholesalers and retailers to expand strategically into new markets.

Rocky Mountain High Brands engages in sales and distribution through online retailers. The Company currently distributes its products to a variety of retail locations, from grocery to convenience to warehouse stores, throughout the United States.

The Company presently markets a lineup of four naturally flavored hemp-infused beverages. These are Citrus Energy, Black Tea, Mango Energy and Lemonade.

In addition, Rocky Mountain High Brands markets a  low-calorie Coconut Lime Energy drink. Moreover, it offers hemp-infused 2 oz. Mango Energy Shots and Mixed Berry Energy Shots.   

Rocky Mountain High Brands has launched its  GPS based geofencing software advertising system in the Los Angeles, California market. Geofencing is the practice of using Global Positioning  (GPS) or radio frequency identification (RFID) to define a geographic boundary. The design of the software package is to interface with mobile devices when a consumer is within proximity of a Rocky Mountain High retailer.

This month, Rocky Mountain High Brands announced that by early next month, Eagle Spirit Spring Water will be available in all nine locations of Central Market. Central Market will carry Eagle Spirit Spring Water in the current 16.9 oz. bottles, the 10-liter water in-a-box containers, as well as a new 1-liter bottle. Central Market is a specialty chain owned and operated by Texas-based HEB Supermarket Company.

Furthermore, Rocky Mountain High Brands recently signed a distribution agreement with KeHE to distribute Eagle Spirit Spring Water. KeHE will give the Company access to national food chains, food services locations, and all natural food stores, among many others. KeHE is a national distribution firm.

Rocky Mountain High Brands, Inc. (RMHB), closed Wednesday's trading session at $0.012, even for the day, on 3,305,103 volume with 89 trades. The average volume for the last 60 days is 10,435,751 and the stock's 52-week low/high is $0.0053/$0.111.


Osprey Gold Development Ltd. (OSSPF)

WatchDog Stocks, Stockhouse, InvestorsHub, Morningstar, MarketWatch, 4-Traders, OTC Markets, Junior Mining Network, Investing News, and Stock Orange reported on Osprey Gold Development Ltd. (OSSPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Osprey Gold Development Ltd. centers on exploring five historically producing gold properties in the Province of Nova Scotia.  Its flagship project is Goldenville, situated in the historical mining district Goldenville, which is one of eastern Canada’s most significant gold belts. The Company has the option to earn 100 percent (subject to certain royalties) in all five properties. This includes the Goldenville Gold Project. Osprey Gold Development has its corporate office in Vancouver, British Columbia.

The Goldenville Gold Project recorded greater than 212,300 ounces of gold production between 1862 and 1942. Goldenville has an updated NI
43-101 inferred resource that includes 2,800,000 tonnes at 3.20 g/t gold for a total of 288,000 ounces of gold (2.8 mil tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped).

Osprey Gold Development is also exploring the past producing Caribou, Lower Seal Harbour, Miller Lake, and Gold Lake gold projects. Osprey Gold entered into a definitive agreement whereby it has acquired an option to acquire the Caribou Gold Property from John Logan Enterprises Ltd. With this Option Agreement, Osprey Gold may acquire a 100 percent interest (subject to certain royalties) in 16 contiguous mining claims (256 hectares) hosting the past-producing Caribou Property.

The Caribou Gold property is 80 kilometers northwest of Halifax, Nova Scotia and 10 kilometers south of the rural community of Upper Musquodoboit, in Halifax County. The Caribou property contains an historic gold deposit that was intermittently mined between 1869 and 1955.

The Miller Lake Project is roughly 14 kilometers from Goldenville. It has historic production and limited recent exploration. The Gold Lake Project is about 70 kilometers northeast of Halifax. It was discovered in 1867 with minor production taking place in the late 1800’s.

The Lower Seal Harbour project is in Guysborough County, Nova Scotia. This property is around 35 kilometers from Goldenville. Gold at Lower Seal Harbour is found in the veins and the host rocks.

This past September, Osprey Gold announced that it completed the latest drilling program at its Goldenville Gold Project near Sherbrooke, Nova Scotia. The program was expanded from 2,500 meters to 3,044 meters. The expanded drill program included an additional hole at the Mitchell Lake prospect area, 4 kilometers to the east of the main Goldenville resource area, and added holes at the Goldenville resource area.

Recently, Osprey Gold announced that it completed surface work at the Lower Seal Harbour gold project near Goldboro, Nova Scotia. The Company’s initial program included geologic mapping, rock sampling, as well as mobile metal ion (MMI) soil geochemistry.

The program also included compilation and analysis of historic data with the objective of generating targets for future exploration and drill programs. A total of 121 samples from the earlier completed surface program were submitted for assay.

Osprey Gold Development Ltd. (OSSPF), closed Wednesday's trading session at $0.061, up 22.00%, on 3,000 volume with 1 trade. The average volume for the last 60 days is 24,180 and the stock's 52-week low/high is $0.045/$0.34.


Isodiol International, Inc. (ISOLF)

Stockhouse, InvestorsHub, OTC Markets, Investopedia, and Wealth Daily reported on Isodiol International, Inc. (ISOLF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Isodiol International, Inc. specializes in the development of pharmaceutical and wellness products. An international Bioactive Phytoceutical innovator, the Company’s growth strategy includes the development of over-the-counter (OTC) and pharmaceutical drugs, and expanding its phytoceutical portfolio. Isodiol is continuing global expansion into Latin America, Asia, and Europe. OTCQB-listed, Isodiol International is headquartered in Vancouver, British Columbia.

The Company is the market leader in pharmaceutical grade phytochemical compounds. Furthermore, it is the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol International is the initiator of numerous firsts for the cannabis industry. This includes commercialization of 99 percent+ pure, bioactive pharmaceutical grade cannabinoids. It also includes micro-encapsulations and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol International produces raw ingredients, consumer packaged goods such as dietary supplements, food and beverages, skin care, and pharmaceutical products for the worldwide healthcare market. Regarding raw ingredients, the Company develops natural phytoceutical derivatives and delivery technologies.

Concerning consumer products, it develops its own family of product brands for retail sale. It also develops white label products and brands for wholesale customers. Pertaining to pharmaceuticals, Isodiol supplies raw phytoceutical ingredients.

Isodiol International Inc announced this month the U.S. sales launch of ImmunAG™. This product is the market’s first non-cannabis cannabidiol (CBD) product derived from the hops plant. This is a time-released tablet. The ImmunAG tablet does not dissolve in the stomach. It dissolves in the lower intestine, therefore creating greater bioactivity.

Isodiol has acquired worldwide licensing rights for IsoDerm™ and five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects Technology™. This is a back of the neck delivery system from its developer Dr. Ronald Aung-Din, MD.

With this innovative non-systemic delivery system, a topical cream can be applied to the back of the neck (at the hairline). It is subsequently picked up by the free nerve endings in the dermis of the skin for a highly effective delivery of the compound.

Last week, Isodiol International announced that it entered into a definitive agreement in connection with its earlier announced Letter of Intent (LOI) to acquire Bradley’s Bioscience, Inc. Bradley’s is a foremost manufacturer and distributer of hemp oil and nicotine e-liquids.

Mr. Marcos Agramont, Isodiol International’s Chief Executive Officer, said, “The acquisition of Bradley’s Bioscience, a market poised to be a $61.4 billion-dollar industry by 2025 is another major milestone for the Company. Not only does this allow the Company to penetrate a new market, but we are now also able to provide consumers with a safer alternative to smoking.  Overall, we believe Bradley’s Bioscience is a perfect fit with Isodiol and our long-term vision and we are very pleased to be moving forward with this agreement.”

Furthermore, Isodiol International has entered into a binding agreement to acquire 100 percent of C3 Global Biosciences (C3GBS). C3GBS is a cause driven organization. Its dedication is to developing sustainable health solutions via the advancement of cannabis science.

Isodiol International, Inc. (ISOLF), closed Wednesday's trading session at $0.5122, up 3.79%, on 308,776 volume with 133 trades. The average volume for the last 60 days is 184,079 and the stock's 52-week low/high is $0.075/$1.69.


WhereverTV Broadcasting Corporation (TVTV)

Stockhouse, Amigo Bulls, Barchart, YCharts, Zacks, MarketWatch, TradingView, AwesomePennyStocks, and StreetInsider reported on WhereverTV Broadcasting Corporation (TVTV), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Established in 2007, WhereverTV Broadcasting Corporation delivers Over the Top  (OTT) subscription television services to a variety of devices. These include smartphones, TabletPCs, streaming media players, computers, and connected TVs. WhereverTV is the next generation subscription television service. It provides consumers with live-streaming, genre-specific, and in-language viewing choices fromaround the world, delivered to anywhere internationally, via any internet enabled device. OTCQB-listed, WhereverTV Broadcasting is based in Fort Myers, Florida.

Current genre specific subscriptions include News channels, faith based channels, and more. Current in-language subscription offerings include Arabic TV, French TV, Italian TV, and Moroccan TV.

QYOU Media has partnered with WhereverTV Broadcasting. QYOU's linear channel of curated video content is featured in the line-up for WhereverTV Latino. This is a service in Mexico that caters to the growing appetite for digital TV in Mexico. QYOU Media is the world's top curator of premium 'best-of-the-web' video for multi-screen distribution. 

The broadcast signals are accessed through the internet through an Over the Top  (OTT) platform. Channel management is handled by WhereverTV’s patented Interactive Program Guide (IPG) technology.

The Company’s platform enables subscribers to access licensed and free-to-air content across devices with the IPG across unlimited geographies, and wherever there exists internet connectivity. Customer viewing experiences are based on customer location (geo-targeting) and content-rights management (subscriptions). WhereverTV owns Digital Rock, Digital Pop, Digital Cross, and other music channels.

WhereverTV Broadcasting has concluded a distribution deal with Vibrant TV. Beginning this month, Vibrant TV will be premiering on WhereverTV’s digital subscription platform’s expansive assortment of quality full-time entertainment networks.  Vibrant TV is a 24/7 linear television network. Vibrant TV airs fresh, never-before-seen entertainment programming from around the world. Its genres include drama, comedy, sports, reality, lifestyle and family.

In addition, this month, WhereverTV Broadcasting announced that it concluded a distribution deal and now provides 10 new channels to United States customers from SPI International/FILMBOX. This includes several featuring numerous language options. WhereverTV is now approaching 100 channel options on its https://Wherever.TV worldwide platform. It is approaching 80 channel options on its https://WhereverLatino.TV Latin American channel platform.

WhereverTV Broadcasting Corporation (TVTV), closed Wednesday's trading session at $0.08375, up 7.37%, on 12,000 volume with 2 trades. The average volume for the last 60 days is 16,735 and the stock's 52-week low/high is $0.07/$0.46.


SCI Engineered Materials, Inc. (SCIA)

InvestorsHub and OTC Markets reported on SCI Engineered Materials, Inc. (SCIA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

SCI Engineered Materials, Inc. is a global supplier and manufacturer of advanced materials for physical vapor deposition (PVD) thin film applications. This includes thin film solar products. The Company works closely with end users and original equipment manufacturers (OEMs) to develop unique, customized solutions. It provides targeted solutions for thin film applications. OTCQB-listed,  SCI Engineered Materials is based in Columbus, Ohio.

The Company is an ISO 9001-2015 Registered Provider of PVD Materials. It is a “Full Service Materials Provider” for PVD applications. SCI is a recognized leader in the development of “Transparent Conductive Oxide (TCO)” materials for varied industries. SCI continues development with Universities and Research Institutes internationally.

SCI provides ceramic and metal targets for use in sputtering and laser ablation systems. Furthermore, the Company manufactures high performance metal, ceramic, and alloy bulk-form evaporation sources in almost any customer defined configuration.

In addition, SCI processes a wide assortment of custom ceramic powders in house. It offers a broad variety of single crystal substrates for making first-class thin films. Services that SCI provides include advanced ceramic powers, vacuum hot pressing, machining, bonding, and quality assurance. The major markets that SCI Engineered Materials serves include architectural glass, optic & photonic, solar photovoltaic, transparent electronics, and solid state lithium thin film battery. The Company provides precision machining of backing plates & tubes to customer or OEM specifications.

SCI Engineered Materials announced in June of last year that it entered into a joint project with Case Western Reserve in their Summer Undergraduate Research in Energy and Sustainability program. The objective of the project is to measure the band gaps and work function of several materials now undergoing development by SCI through in-house research and development (R&D) activities.

Case Western Reserve was to evaluate test films to determine if SCI's materials have superior properties to replace Cadmium Sulfide and/or intrinsic Zinc Oxide in Copper Indium Gallium Selenide (CIGS) thin film solar products.

Subsequent, SCI Engineered Materials announced Case Western Reserve University’s (CWRU) successful evaluation of test films utilizing SCI’s Zinc Magnesium Oxide (MZO) material. The results support use of SCI’s innovative material in thin film solar applications that could lead to higher efficiencies. Yesterday, SCI Engineered Materials reported its financial results for the twelve months and three months ended December 31, 2017.

Mr. Dan Rooney, the Company’s President & Chief Executive Officer, said, “The positive 2017 results can be attributed to changes in the strategy we implemented during in the second half of 2016. These achievements included a 24 percent increase in revenue, a 45 percent increase in gross profit and a 12 percent decrease in operating expenses compared to 2016; resulting in net income of $6,091 compared to a net loss of $(706,054) in 2016. EBITDA for the year 2017 was more than $519,000, the highest annual amount since 2010.”


SCI Engineered Materials, Inc. (SCIA), closed Wednesday's trading session at $1.35, up 10.20%, on 1,000 volume with 3 trades. The average volume for the last 60 days is 7,794 and the stock's 52-week low/high is $0.62/$1.56.


Black Cactus Global, Inc. (BLGI)

Stockopedia, Dividend Investor, PennyStockHub, StreetInsider, Stockwolf, Barchart, InvestingNewsAlerts, Stock Press Daily, InvestorsHub, OTC Markets, Insider Financial, 4-Traders, Morningstar, Stockhouse, Simply Wall St, MarketNewsUpdates, TipRanks, InvestorsHangout, and The Street reported on Black Cactus Global, Inc. (BLGI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Black Cactus Global, Inc. is a technology development company based in Las Vegas, Nevada. The Company focuses on Blockchain, machine learning, cryptocurrency, and the Internet of Things (IoT). Its mission is to pioneer the application of Blockchain and overlapping technologies to protect IP (Intellectual Property) and the security of data and financial transactions. Black Cactus Global lists on the OTC Markets’ OTCQB.

Black Cactus Global’s strategic plan is to become the first completely integrated digital financial institution with Blockchain technology as its operating foundation. The Company specializes in worldwide development and consulting projects in its key development areas of FinTech, digital media, financial services, KYC, AML, cyber security, and healthcare.

Black Cactus Global is developing Blockchain applications for Fintech, Healthcare, Media and Supply Chain utilizing smart contracts and machine learning.

The Company’s services include Blockchain Applications, Trading Exchange, KYC/AML Biometrics, Music Exchange, and Card Programs and Payment Systems. In addition, its services include Crypto Currencies, Internet of Things (IoT), Smart Contracts, and Fintech & Medtech.

Black Cactus Global announced this past January that it entered into an MOU with the majority shareholders in an Indian Technology firm to form a subsidiary of the Company. With this MOU, Black Cactus will become the largest stakeholder of an international Technology company with offices in the ‘FinTech Valley’ Vizag Software Technology Park in Visakhapatnam, India, through which it will center on and advance the use of its unique Blockchain based IP.

Last week, Black Cactus Global announced that it completed a share exchange agreement with the Blockchain development subsidiary, Black Cactus Global Technologies Pvt. Limited (BCG-TPL). This agreement calls for Black Cactus Global to own an initial 29 percent interest in BCG-TPL, which has already attained major milestones that will enable the Company to scale-up development activities. The modern facility will house one of the larger Blockchain development teams.

Today, Black Cactus Global announced that it has withdrawn its participation in a plan to acquire a bank in Iceland with NSB Holdings ehf, for the purpose of creating the first completely digital bank. It concluded, after a strategic review, that the plan would involve many competitive risks, which would impact the economic feasibility of such a project. It also concluded that it would divert Black Cactus Global’s focus away from its main activity, which is the development of Blockchain applications for the efficient management of financial and administrative processes across numerous industries.

Black Cactus Global, Inc. (BLGI), closed Wednesday's trading session at $0.137, up 5.38%, on 1,436,981 volume with 181 trades. The average volume for the last 60 days is 501,097 and the stock's 52-week low/high is $0.0322/$0.838.


Arizona Mining, Inc. (WLDVF)

Stockstream, MarketWatch, InvestorPoint, Stockhouse, The Street, 4-Traders, Morningstar, Resource World, InvestorsHub, Northern Miner, 24hgold, Mining Stock Valuator, WalletInvestor, CapitalCube, InvestorNetwork, GuruFocus, YCharts, Stockwatch, The Stock Market Watch, Predict Wall Street, OTC Markets, GoldStockData, and Stock Target Advisor reported on Arizona Mining, Inc. (WLDVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Arizona Mining, Inc. is a mineral exploration and development company listed on the OTC Markets. It concentrates on the exploration and development of its 100 percent-owned Hermosa Project positioned in Santa Cruz County, Arizona. Arizona Mining’s Projects also include the Taylor Deposit and the Central Deposit.

The Company was previously known as AZ Mining, Inc. It changed its name to Arizona Mining, Inc. in October of 2015. The Company is based in Vancouver, British Columbia.

The Hermosa property is approximately 80 kilometers southeast of Tucson, Arizona. It is roughly 13 kilometers north of the U.S. border with Mexico. Arizona Mining land holdings currently comprise patented mining claims totaling roughly 535 acres and unpatented mining claims totaling around 19,015 acres.

The Taylor Deposit is a zinc-lead-silver carbonate replacement deposit. The Taylor Deposit remains open to the north, west and south over land controlled by Arizona Mining. It will be aggressively drilled to test the limits of the resource.

Arizona Mining’s other project on the Hermosa property is the Central Deposit. This is a silver-manganese manto oxide project.

Strategic priorities for Arizona Mining this year include obtaining key state permits to commence construction of the tailings facility and water treatment plant. Priorities also include obtaining all approvals necessary to start twin exploration decline by Q3 2018.

Additionally, priorities include testing the exploration potential of the Taylor deposit, and delivering a Feasibility Study (FS) on the Taylor Project in Q3 2018.

Yesterday, Arizona Mining announced strong results for two drill holes from the present program centered on expansion of the Taylor Deeps Zone (TDS) situated on the Company’s 100 percent-owned Hermosa Project in Santa Cruz County, Arizona.

Mr. Don Taylor, Chief Operating Officer, said, “Our exploration drilling continues to confirm high-grade extensions to major areas of mineralization identified in the updated PEA. Exploration drilling in the southwestern portion of the Trench property, especially to the south, continues to demonstrate potential for high-grade expansion of the Taylor Deeps Zone. In addition to the continued high-grade zinc-lead-silver mineralization, the current and previous drilling has identified an area of potentially significant copper which is open to the north and south.”

Arizona Mining, Inc. (WLDVF), closed Wednesday's trading session at $3.2043, down 0.58%, on 16,185 volume with 25 trades. The average volume for the last 60 days is 16,821 and the stock's 52-week low/high is $1.4736/$5.90.


TimefireVR, Inc. (TFVR)

Marketwired, InvestorsHub, Barchart, Stockhouse, MarketWatch, and Street Register reported on TimefireVR, Inc. (TFVR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TimefireVR, Inc.  (d/b/a TeraForge) is a technology company centered on strategic investments in blockchain and cryptocurrency technologies. TeraForge is forging financial and technical innovation for blockchain enterprises via investments in tools, systems, and applications, which will provide support for the blockchain and digital currency industries. TeraForge is headquartered in Scottsdale, Arizona.

TeraForge is working to acquire young companies and also pure technology teams in an array of blockchain related fields. It has made an investment directly in ethereum and purchased bitcoin mining equipment located at Colocation Guard.

Last week, TeraForge announced that it entered into an agreement to purchase bitcoin mining equipment to be installed at ColocationGuard in Brooklyn, New York. Led by Mr. Donald D’Avanzo, Director of Datacenter Operations, about 20 Antminer S9 Bitcoin Mining units were installed. They have been running for about three weeks.

After successful Phase I implementation and operational execution of the first mining units, the Company has invested in 20 additional S9 antminers plus 82 new L3 Litecoin antminers. This is to improve the project hash rate.

Thirty-two new GPU mining rigs comprising a total of 192 Nvidia Geforce GTX 1070 cards will be brought online to diversify the portfolio of cryptocurrency altcoins mined. The new units will allow TeraForge to mine the top five most profitable GPU altcoins. These are Ethereum, Ethereum Classic, Monero, ZCash, as well as Ubiq.

ColocationGuard Enterprise Solutions, LLC (ColocationGuard) operates more than 60,000 square feet of colocation space in Brooklyn and Northern New Jersey. It delivers 1Gig to 100Gig connections by way of manifold Tier1 providers with Points of Presence in the facility. ColocationGuard is Brooklyn’s only data center and carrier-neutral hotel for all major fiber providers.

Furthermore, TeraForge is working closely with ColocationGuard Executive Leadership. This is to secure one of only three available anchor tenant slots in a new state-of-the-art dedicated mining facility located within the Northeast.

TimefireVR, Inc. (TFVR), closed Wednesday's trading session at $0.0055, even for the day, on 3,329,299 volume with 39 trades. The average volume for the last 60 days is 2,974,624 and the stock's 52-week low/high is $0.0054/$0.185.


The QualityStocks Company Corner

BLOCKStrain Technology Corp. (TSXV: DNAX)

The QualityStocks Daily Newsletter would like to spotlight BLOCKStrain Technology Corp. (DNAX).

On behalf of BLOCKSTRAIN TECHNOLOGY CORP. (TSXV: DNAX) (formerly Scorpion Resources Inc.) (NEX:SR.H) (the "Company"), was pleased to announce that trading began today in shares of the company on the TSX Venture Exchange ("TSXV") under the stock symbol 'DNAX.'

BLOCKStrain Technology Corp. (TSX.V: DNAX), a full-service software company headquartered in Vancouver, BC, Canada, has developed the first integrated blockchain platform that registers and tracks cannabis intellectual property (“IP”) from genome to sale. It is proprietary, immutable and cryptographically secure, thereby establishing a single source of truth for cannabis strains and their ownership.

With Canada set to legalize marijuana use for recreational purposes, and other jurisdictions following suit around the world, new challenges will emerge regarding the ability to provide a safe and legal inventory of a product that up until now was largely only available on the black market. Cannabis will be heavily tested and regulated by numerous regulatory bodies in Canada. The cannabis industry faces unique challenges that BLOCKStrain specifically helps it address, including:

  • Mandatory Testing: Through BLOCKStrain’s platform and lab-testing partners, the process is more efficient and streamlined, cutting the administrative burden in half and getting products to market faster;
  • DNA Based Product Validation: The underlying blockchain technology creates a genetic fingerprint that identifies and validates the product electronically so any participant on the platform, including consumers, can view and track what’s happening with that product from genome to sale;
  • Intellectual Property: Third, and perhaps most importantly, the BLOCKStrain platform protects the intellectual property of growers and breeders. This is important for the industry’s growth as products evolve and develop. If a craft grower, for example, creates a popular strain with unique characteristics, it will be able to protect its intellectual property by simply registering the strain’s genome with BLOCKStrain and locking that data into the blockchain. It will reside there forever and will be readily accessible in the event of future disputes, bringing a level of trust to the industry and ensuring licensing fees are paid to all players in the market.


BLOCKStrain’s genetics verification process is authentic and incredibly effective. User groups register by creating an account with BLOCKStrain, which starts the process. Organizations and independent growers submit seeds, flower and post-extraction product for testing to a registered and approved testing facility, which then submits test results to BLOCKStrain. Pre-existing data of genetic cannabis strains can also be submitted via BLOCKStrain verification administrators, with those results being added to the user group’s blockchain account. Submissions are entered into BLOCKStrain, and the transaction is completed and recorded.

Each time an item is tested and verified by the network, a Registration Affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but can also rate the product, write reviews and share opinions. This detail is stored within BLOCKStrain and, just like the test results, cannot be tampered with or modified. Verification and certification are earned by all parties for their participation.


BLOCKStrain demystifies the seed-to-sale process for all relevant stakeholders including producers, distributors, shippers, government agencies and consumers by creating a repository of cannabis genomes on an immutable, shared ledger. Thousands of cannabis strains exist and cultivators are breeding new strains all the time. The proliferation of cannabis strains can prove problematic for consumers since there are more than 500 known chemical compounds in a single plant. Furthermore, since several dozens of these compounds have been identified as pharmacologically active, it becomes more and more difficult for consumers to know what they are purchasing.

It is for this reason that being able to quantify the genetics, potency and equivalencies among cannabis products is crucial to the future of legalized cannabis. The difference is not so much in the name or brand attached to the cannabis, but the DNA of the plant itself. BLOCKStrain ensures product integrity, safety, regulatory compliance, product licensing and authenticity – all vital elements for the emerging cannabis industry.  This technology also bolsters the process of meeting government regulatory standards by providing real-time visibility of industry operations to agencies assigned to enforce and regulate cannabis activity.


BLOCKStrain allows for the defense of intellectual property rights for the grower with an authentic, verifiable chain of evidence embedded in the blockchain itself. Proof of ownership for a specific strain of cannabis is paramount in a multibillion dollar industry. Real life ownership disputes have already begun in the industry with legal battles underway. Unfortunately, the framework for resolving these disputes has yet to be defined and they are not likely to be resolved anytime soon.

Consumers and regulators alike want to know whether a cannabis product grown and sold at a local dispensary is safe and meets quality control standards. BLOCKStrain enhances trust of origin from genome-to-sale as cannabis flows through the supply chain, verifying critical steps in the process such as who is growing the plant, which seed is planted and where did it come from, whether pesticides were used, how much was grown, which tests are used to establish quality and potency, where the product is transported and how, and whether possession limits are meeting regulatory standards.

In summary, BLOCKStrain has developed the most comprehensive, secure and community-driven cannabis genetics archival platform for cannabis breeders and growers, large and small, to protect and release their varieties into the public domain, all while compensating and rewarding them for their contributions.

BLOCKStrain Technology Corp. (DNAX), closed the day's trading session at $1.06, up 253.33%, on 627,130 volume. The stock's 52-week low/high is $0.10/$0.30.

Recent News


PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) announces that, further to shareholder approval of a forward stock split (the "Stock Split") of the Company's issued and outstanding common shares (each, a "Share") on the basis of five new Shares for each one existing Share (see news release dated May 17, 2018), the Company's Shares have commenced trading today on the Canadian Securities Exchange on an "ex-distribution" basis.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.20, up 313.43%, on 14,951 volume with 9 trades. The average volume for the last 60 days is 16,920 and the stock's 52-week low/high is $0.002/$0.16.

Recent News


QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp. (TSX.V: QMC) (FSE: 3LQ) (OTC PINK: QMCQF) (QMC.V) ("QMC" or "the Company") is pleased to report that it has engaged SGS Canada Inc. ("SGS") to provide technical support and consulting services for the company's 2018 field exploration and drilling program at the Irgon Lithium Mine Property, located within the Winnipeg River Pegmatite Field, S.E. Manitoba. Also today, the company was featured in an article detailing how the lithium market continues to experience exponentially rising value as demand for lithium rises rapidly due to the increasing popularity of lithium-ion batteries, largely in part due to the electric vehicle (EV) revolution.

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.46, off by 0.02%, on 152,548 volume with 67 trades. The average volume for the last 60 days is 166,554 and the stock's 52-week low/high is $0.0748/$1.46.

Recent News


Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lithium Chile (TSX.V:LITH) (OTCQB:LTMCF), a client of NNW focused on advancing a lithium property portfolio consisting of 148,500 hectares covering sections of 13 salars and one laguna complex in Chile. To view the full publication, titled “Motherlode Lithium,” visit:

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.6899, off by 0.26%, on 1,300 volume with 2 trades. The average volume for the last 60 days is 1,549 and the stock's 52-week low/high is $0.6599/$0.9021.

Recent News


Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF) wholly-owned subsidiary, Natural Health Services Ltd. ("NHS"), Canada's largest referral network of medical cannabis patients to Licensed Producers ("LPs") in Canada, is holding an open house for media and the public on Wednesday, May 30 at the grand opening of its clinic located at 7900 Anchor Drive in Windsor, Ontario. Also today, CannabisNewsWire released a report on the company detailing how SNNVF joins a growing cadre of voices lauding the U.S. Supreme Court’s recent decision to strike down a federal ban on sports gambling.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $5.996, up 0.32%, on 13,813 volume with 57 trades. The average volume for the last 60 days is 35,489 and the stock's 52-week low/high is $5.90/$16.00.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th. Also today, CannabisNewsWire released a report on the company detailing how LXRP is at the forefront of the growing trend to develop lower-risk technologies that deliver nicotine without the deadly effects of traditional cigarettes.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.52, up 0.66%, on 153,487 volume with 183 trades. The average volume for the last 60 days is 186,180 and the stock's 52-week low/high is $0.27/$2.54.

Recent News


Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), e-commerce and mobile devices, announced that its subsidiary Unified Payments has launched an intelligent payment solution for the events industry.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.45, off by 1.59%, on 89,660 volume with 464 trades. The average volume for the last 60 days is 935,899 and the stock's 52-week low/high is $2.556/$33.51.

Recent News


Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (NASDAQ and TASE: FRSX), today reported financial results for the first quarter of 2018. Foresight ended the first quarter of 2018 with $16.7 million in cash and short-term deposits, GAAP net profit of $2.6 million and non-GAAP net loss of $3.5 million. Also today, NetworkNewsWire released a report on the company detailing how FRSX’s Given the focus on self-driving cars in recent years, a lot of public and press attention was on what detection systems could bring to the autonomous vehicle game, and QuadSight’s unique features caught people’s eyes. To view the full publication, titled “Sensor System Companies Take Center Stage in a Self-Driving Future,” visit:

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $2.8781, off by 0.41%, on 17,738 volume with 35 trades. The average volume for the last 60 days is 24,627 and the stock's 52-week low/high is $2.44/$11.70.

Recent News


First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

US Cobalt Inc. (TSXV:USCO) (Frankfurt:26X) (OTCQB:USCFF), which is to be merged with First Cobalt Corp (TSX-V:FCC) (ASX:FCC) (OTCQX:FTSSF), is pleased to announce first results from its 2018 underground drill program at the Iron Creek project (the "Property") in Idaho, USA.  All three holes encountered significant cobalt mineralization, extending the known mineralization to over 1,700 feet (520 meters) along strike. Also today, NetworkNewsWire released a report on the company detailing how FTSSF is focused on creating the largest pure-play cobalt exploration and development company in the world. To view the full publication, titled “Growing Cobalt Industry Looks to Escape Reliance on DRC,” visit: Additionally, NetworkNewsWire announced the online availability of its new interview with FTSSF. The interview can be heard at

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.595, off by 4.03%, on 55,300 volume with 37 trades. The average volume for the last 60 days is 120,762 and the stock's 52-week low/high is $0.3148/$1.3041.

Recent News


ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the launch of its new medical cannabis brand, Beacon Medical. To view the full press release, visit:

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” ABcann Global CEO Barry Fishman said.

ABcann Global owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

ABcann has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by ABcann’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting ABcann’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

ABcann’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with ABcann’s philosophy of quality and innovation.

ABcann’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, ABcann also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

ABcann Global (ABCCF), closed the day's trading session at $1.21, off by 1.47%, on 149,930 volume with 167 trades. The average volume for the last 60 days is 278,915 and the stock's 52-week low/high is $0.65/$3.2929.

Recent News


Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ).

Epazz, Inc. (OTC: EPAZ), a leading provider of cloud-based business software solutions, has reported its unaudited first quarter results for 2018. The company reported revenue of $474,145 compared with $473,974 for the first quarter of 2017. The company reported a net income of $15,050.

Epazz, Inc. (EPAZ) is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company’s strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

“We are starting 2018 with ZenaPay on both major mobile apps’ platforms,” said Shaun Passley, PhD, CEO and founder of Epazz. “We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company.”

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz’s unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

“Blockchain-based technology is the future of the Internet,” Passley said. “Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come.

Epazz, Inc. (EPAZ), closed the day's trading session at $0.08, up 5.68%, on 23,885 volume with 10 trades. The average volume for the last 60 days is 155,606 and the stock's 52-week low/high is $0.0045/$0.52.

Recent News


Pivot Pharmaceuticals Inc. (PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) is pleased to announce that its wholly-owned U.S. subsidiary, Pivot Naturals LLC, ("PNL"), has executed a lease agreement for a manufacturing facility in Costa Mesa, California's Measure "X" Zone.

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.478, off by 12.81%, on 144,436 volume with 88 trades. The average volume for the last 60 days is 117,628 and the stock's 52-week low/high is $0.047/$2.46.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.